February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
10 citations
,
December 2023 in “International Journal of Nanomedicine” Cell membrane-coated nanoparticles could improve gene therapy by enhancing delivery and targeting of nucleic acids.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
29 citations
,
July 2008 in “British Journal of Dermatology” The patient had paraneoplastic pemphigus without mucosal involvement.
84 citations
,
October 2007 in “The Journal of Immunology” Myeloid-derived suppressor cells help control autoimmune cells and promote hair regrowth in alopecia areata.
17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
August 2021 in “BMJ Case Reports” A woman with lupus had blood cell destruction, treated successfully with medication.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
April 2023 in “Journal of Investigative Dermatology” Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.
May 2018 in “The Journal of Immunology” A(1-7) treatment reduces symptoms of lupus in mice.
54 citations
,
October 2024 in “Nature Communications” Molybdenum oxide nanozymes can effectively treat and monitor acute kidney injury by reducing oxidative stress.
130 citations
,
October 2006 in “Allergy” Allergic reactions to blood thinners are rare but can be serious, requiring careful testing and alternative treatments.
1 citations
,
September 2023 in “Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)” Avian yolk antibodies offer a promising, ethical alternative for disease prevention and therapy.
January 2024 in “Circulation” Certain genetic mutations can lower bad cholesterol and reduce heart disease risk, leading to effective cholesterol-lowering drugs.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
2 citations
,
December 1997 in “Journal of The American Academy of Dermatology” The document concludes that doctors should monitor children's brain development when treating hemangiomas with interferon alfa and consider stopping the treatment if problems arise, while also exploring drugs that might counteract side effects.
January 2026 in “Advances in Clinical and Experimental Medicine” Regulatory T cells and mesenchymal stem cells work together to prevent immune system overreactions and tissue damage.
October 2021 in “Journal of Investigative Dermatology” Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
A 16-year-old girl with lupus symptoms improved with treatment despite negative ANA tests.
28 citations
,
March 2013 in “Journal of Investigative Dermatology” Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
January 2020 in “SSRN Electronic Journal” Different autoantibody groups in pediatric SLE are linked to specific symptoms and disease outcomes.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
August 2021 in “Journal of Investigative Dermatology” ILC1-like cells can cause alopecia areata by disrupting hair follicle immunity, suggesting a new treatment approach.
1 citations
,
November 1991 in “PubMed” Immunoadsorption successfully treated a man's resistant polymyositis.